Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are effective GLP-1 receptor agonists used for weight loss, but their safety profiles are slightly different. Neither drug is inherently "unsafe," but depending on your medical history and tolerance, …
Which is safer, Mounjaro or Wegovy?
Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are effective GLP-1 receptor agonists used for weight loss, but their safety profiles are slightly different. Neither drug is inherently “unsafe,” but depending on your medical history and tolerance, one may be a better fit for you than the other.
Let’s break down what makes one safer over the other in specific scenarios.
1. Mechanism of action
- Wegovy: Contains semaglutide, a GLP-1 receptor agonist that reduces appetite, slows digestion, and improves blood sugar.
- Mounjaro: Contains tirzepatide, which acts on two hormones—GLP-1 and GIP—making it more powerful, but possibly harder to tolerate for some.
Because Mounjaro stimulates more pathways, it may cause stronger effects—both positive and negative.
2. Common side effects
Both medications share similar side effects, such as:
- Nausea
- Vomiting
- Diarrhea or constipation
- Fatigue
- Reduced appetite
However, Mounjaro tends to cause more frequent or intense GI issues, especially during dose escalation.
Verdict:
If you’re prone to digestive sensitivity, Wegovy may be slightly easier to tolerate.
3. Serious risks and black box warnings
Both Mounjaro and Wegovy carry a black box warning for:
- Thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)
- MEN2 (Multiple Endocrine Neoplasia syndrome type 2)
Neither drug is recommended if you or a close relative has a history of these conditions.
In addition, both can potentially cause:
- Pancreatitis
- Gallbladder disease
- Low blood sugar (more so if combined with other diabetes medications)
Verdict:
Equally risky for patients with a history of thyroid or pancreas issues. You must be screened before starting either.
4. Cardiovascular safety
Wegovy has published clinical data proving it reduces risk of heart attack, stroke, and cardiovascular death in people with obesity and heart disease.
Mounjaro’s cardiac data is still pending, although early results are promising.
Verdict:
If you have heart disease, Wegovy may be the safer and better-studied option (for now).
5. Long-term experience and availability
- Wegovy has been FDA-approved since 2021, with more real-world data on side effects, safety, and patient outcomes.
- Mounjaro (Zepbound) was approved for weight loss in late 2023, and while results are impressive, it has less long-term safety data.
Verdict:
Wegovy has the benefit of being better understood in clinical practice.
Final comparison: which is safer overall?
| Factor | Wegovy | Mounjaro |
|---|---|---|
| GI Side Effects | Milder | Stronger |
| Thyroid/Pancreas Risk | Equal | Equal |
| Heart Disease Data | Strong + published | Promising but limited |
| Time on Market | Longer use, more data | Newer, less data |
| Effectiveness | Up to 15% weight loss | Up to 22% weight loss |
Bottom line:
Wegovy is generally considered safer for people with sensitive digestion, heart conditions, or who prefer a better-studied option. Mounjaro may be more effective, but slightly riskier in terms of GI side effects and unknowns due to its newer status.
Always talk to a provider to determine which medication is safer based on your health profile.
If symptoms get worse or don’t improve, visit your local urgent care provider for professional evaluation.
Hey Did You Know We Have an IV Therapy Spa Inside? Check out our drip menu!
